Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study
暂无分享,去创建一个
E. Ricci | A. De Vito | G. Cenderello | K. Falasca | A. Cascio | P. Bonfanti | L. Taramasso | A. di Biagio | G. Parruti | C. Martinelli | G. Pellicanò | G. Orofino | B. Celesia | C. Molteni | G. Madeddu | G. D. De Socio | N. Squillace | B. Menzaghi | L. Valsecchi | Cecilia Costa | E. Sarchi | Cecilia Costa | Eleonora Sarchi
[1] M. Fabbiani,et al. Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study , 2022, Medicine.
[2] F. Serapide,et al. Weight of Clinical and Social Determinants of Metabolic Syndrome in People Living with HIV , 2022, Viruses.
[3] L. Calza,et al. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. , 2021, AIDS patient care and STDs.
[4] G. d’Ettorre,et al. Efficacy and durability of two‐ vs. three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE cohort , 2021, HIV medicine.
[5] A. Milinkovic,et al. Factors associated with overweight/obesity in a cohort of people living with HIV over 50 years of age , 2021, AIDS care.
[6] E. Tamburrini,et al. Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV. , 2021, Journal of acquired immune deficiency syndromes.
[7] G. di Perri,et al. The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV , 2021, Expert opinion on drug metabolism & toxicology.
[8] A. Antinori,et al. Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era , 2021, AIDS (London, England).
[9] M. Law,et al. Treatment Modification after Second-Line Failure among People Living with HIV in Asia-Pacific , 2020, Antiviral therapy.
[10] S. Oka,et al. Virological failure and HIV drug resistance among adults living with HIV on second‐line antiretroviral therapy in the Asia‐Pacific , 2020, HIV medicine.
[11] G. d’Ettorre,et al. Overall tolerability of Integrase Inhibitors in clinical practice: results from a multicenter Italian cohort. , 2020, AIDS research and human retroviruses.
[12] D. Cattaneo,et al. Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV , 2020, Clinical Pharmacokinetics.
[13] A. Calcagno,et al. A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs , 2020, Journal of NeuroVirology.
[14] E. Ricci,et al. Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort , 2020, Infection and drug resistance.
[15] G. d’Ettorre,et al. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: Results from a multicenter cohort study. , 2019, Antiviral research.
[16] A. Giacomelli,et al. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV‐infected patients in clinical practice: results from a multicentre, observational study , 2018, HIV medicine.
[17] E. Ricci,et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA) , 2018, BMC Infectious Diseases.
[18] A. d’Arminio Monforte,et al. First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison , 2018, HIV medicine.
[19] L. Calza,et al. Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project , 2018, Infection and drug resistance.
[20] L. Calza,et al. Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project , 2017, PloS one.
[21] A. De Luca,et al. Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. , 2017, AIDS.
[22] N. Ford,et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. , 2016, The lancet. HIV.
[23] J. Gallant,et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. , 2016, The New England journal of medicine.
[24] Stephen T. Wright,et al. Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study. , 2016, Sexual health.
[25] M. Fox,et al. Changes in second-line regimen durability and continuity of care in relation to national ART guideline changes in South Africa , 2016, Journal of the International AIDS Society.
[26] H. Lane,et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.
[27] E. Ricci,et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. , 2015, International journal of antimicrobial agents.
[28] Richard D Moore,et al. Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil , 2014, BMC Infectious Diseases.
[29] A. d’Arminio Monforte,et al. Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort , 2014, Journal of the International AIDS Society.
[30] S. Lewin,et al. The end of AIDS: HIV infection as a chronic disease , 2013, The Lancet.
[31] J. Sterne,et al. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009 , 2012, AIDS.
[32] E. Ricci,et al. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study , 2012, AIDS.
[33] A Cozzi-Lepri,et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral‐naïve patients , 2010, HIV medicine.
[34] S. Cole,et al. Short-term discontinuation of HAART regimens more common in vulnerable patient populations. , 2008, AIDS research and human retroviruses.
[35] R. Weber,et al. Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study. , 2008, The Journal of infectious diseases.
[36] E. Ricci,et al. An Italian Approach to Postmarketing Monitoring: Preliminary Results From the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) Project on the Safety of Lopinavir/Ritonavir , 2005, Journal of acquired immune deficiency syndromes.
[37] A. Luber,et al. Open Access Journal of the International Aids Society Genetic Barriers to Resistance and Impact on Clinical Response , 2005 .
[38] J. Arribas. The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens. , 2004, The Journal of antimicrobial chemotherapy.
[39] V. Soriano,et al. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. , 2003, AIDS.
[40] M. Moroni,et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.